Malvern, PA - YPrime announces the release of its data-driven electronic clinical outcome assessment (eCOA) technology platform. Designed to capture endpoints from multiple modalities and streamline patient data collection in clinical trials, YPrime's eCOA technology supports sponsors, sites and patients while delivering consumer-friendly applications built on the best standards of user experience principles.
YPrime's eCOA solutions offer data capture in virtually any clinical research setting, with features that promote user convenience, compliance and data integrity:
"YPrime's approach to eCOA is a great example of our collective efforts to uncomplicate patient data collection," said Shawn Blackburn, CEO and co-founder. "This platform, which offers the most advanced features in the marketplace, provides the tools that make clinical endpoint collection quicker, easier and considerably less frustrating. Technology that focuses on the end user's experience, particularly for site and patients will have a landmark effect on the way we conduct clinical trials in the future."
About YPrime
YPrime offers more than a decade of focused work with eclinical systems to expedite and improve the quality of patient management, clinical supplies, drug accountability and clinical data. Cloud-based interactive response technology (IRT) and electronic clinical outcome assessment (eCOA) platforms enable greater speed, precision and integration in clinical trial management. Our data services tools help sponsors bring together fragmented clinical research data into contextual information they can act on. YPrime's technology and service offerings enable sponsors to move faster and more efficiently to their next development milestone.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma
July 22nd 2025The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (NCT03767348) trial in advanced melanoma was not an adequate, well-controlled study and that its heterogeneous patient population limited interpretability, preventing approval in its current form.